gvax prostate cancer vaccine
Vaccineexperimental
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
8
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 1998 (NCT00140374)
Timeline
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108618 ↗
- ChEMBLCHEMBL2108031 ↗
Also known as
- allogeneic prostate vaccine
- cg1940
- cg-1940
- galgenprostucel-l
- gvax prostate
- gvax prostate
- gvax prostate cancer vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00771017 | Phase 2 | Jul 1, 2008 | Eastern Cooperative Oncology Group, Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00577356 | Phase 2 | Feb 1, 2008 | Cell Genesys, Sanofi, Virginia Mason Medical Center |
| NCT00133224 | Phase 3 | Jul 1, 2005 | Cell Genesys |
| NCT00089856 | Phase 3 | Jul 1, 2004 | Cell Genesys |
| NCT00140348 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2001 | Cell Genesys |
| NCT00140387 | Phase 1/Phase 2 (Phase 2) | May 1, 1999 | Cell Genesys |
| NCT00140400 | Phase 1/Phase 2 (Phase 2) | May 1, 1999 | Cell Genesys |
| NCT00140374 | Phase 1/Phase 2 (Phase 2) | Dec 1, 1998 | Cell Genesys |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cell Genesys | For profit | 7 | 6 | 2 | 1998 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2008 |
| Sanofi | For profit | 1 | 0 | 1 | 2008 |
| Virginia Mason Medical Center | Academic/Hospital | 1 | 1 | 1 | 2008 |
6 organizations
Page 1 / 1